MX2023012368A - Vacuna de virus. - Google Patents
Vacuna de virus.Info
- Publication number
- MX2023012368A MX2023012368A MX2023012368A MX2023012368A MX2023012368A MX 2023012368 A MX2023012368 A MX 2023012368A MX 2023012368 A MX2023012368 A MX 2023012368A MX 2023012368 A MX2023012368 A MX 2023012368A MX 2023012368 A MX2023012368 A MX 2023012368A
- Authority
- MX
- Mexico
- Prior art keywords
- virus
- infection
- agents
- amino acid
- disclosure relates
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 5
- 229960005486 vaccine Drugs 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 230000009385 viral infection Effects 0.000 abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 208000025721 COVID-19 Diseases 0.000 abstract 1
- 208000001528 Coronaviridae Infections Diseases 0.000 abstract 1
- 208000037847 SARS-CoV-2-infection Diseases 0.000 abstract 1
- 230000005867 T cell response Effects 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000005875 antibody response Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2021060273 | 2021-04-20 | ||
| PCT/EP2022/060417 WO2022223617A1 (en) | 2021-04-20 | 2022-04-20 | Virus vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023012368A true MX2023012368A (es) | 2023-11-01 |
Family
ID=81579467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023012368A MX2023012368A (es) | 2021-04-20 | 2022-04-20 | Vacuna de virus. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240383947A1 (https=) |
| EP (1) | EP4326317A1 (https=) |
| JP (1) | JP2024517642A (https=) |
| KR (1) | KR20240009419A (https=) |
| CN (1) | CN117750974A (https=) |
| AU (1) | AU2022260466A1 (https=) |
| BR (1) | BR112023021654A2 (https=) |
| CA (1) | CA3215771A1 (https=) |
| IL (1) | IL307762A (https=) |
| MX (1) | MX2023012368A (https=) |
| WO (1) | WO2022223617A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| CN117153245B (zh) * | 2023-10-18 | 2024-03-19 | 无锡市疾病预防控制中心 | 预测新型冠状病毒S蛋白RBD区域与hACE2受体相互作用的方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| US7176278B2 (en) | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| EP1900753B1 (en) | 2002-11-08 | 2017-08-09 | Ablynx N.V. | Method of administering therapeutic polypeptides, and polypeptides therefor |
| HUE027902T2 (en) | 2004-02-09 | 2016-11-28 | Human Genome Sciences Inc Corp Service Company | Albumin fusion proteins |
| US20070269422A1 (en) | 2006-05-17 | 2007-11-22 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| CN101511868B (zh) | 2006-07-24 | 2013-03-06 | 比奥雷克西斯制药公司 | 毒蜥外泌肽融合蛋白 |
| AU2007293614A1 (en) | 2006-09-08 | 2008-03-13 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| WO2009083804A2 (en) | 2007-12-27 | 2009-07-09 | Novartis Ag | Improved fibronectin-based binding molecules and their use |
| EA201001734A1 (ru) | 2008-05-02 | 2011-10-31 | Новартис Аг | Улучшенные связывающие молекулы на основе фибронектина и их применение |
| EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
| EP2493871B1 (en) | 2009-10-30 | 2014-09-03 | Domain Therapeutics | Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| EP2556087A1 (en) | 2010-04-09 | 2013-02-13 | Novozymes Biopharma DK A/S | Albumin derivatives and variants |
| EP2558491B1 (en) | 2010-04-13 | 2018-07-04 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind pcsk9 |
| EP2758436B1 (en) | 2011-09-23 | 2019-06-12 | Universität Stuttgart | Serum half-life extension using immunoglobulin binding domains |
| EP2780364A2 (en) | 2011-11-18 | 2014-09-24 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| WO2016005004A1 (en) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
| WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
-
2022
- 2022-04-20 BR BR112023021654A patent/BR112023021654A2/pt not_active Application Discontinuation
- 2022-04-20 WO PCT/EP2022/060417 patent/WO2022223617A1/en not_active Ceased
- 2022-04-20 JP JP2023564119A patent/JP2024517642A/ja active Pending
- 2022-04-20 EP EP22720733.9A patent/EP4326317A1/en active Pending
- 2022-04-20 IL IL307762A patent/IL307762A/en unknown
- 2022-04-20 CN CN202280043287.9A patent/CN117750974A/zh active Pending
- 2022-04-20 US US18/287,608 patent/US20240383947A1/en active Pending
- 2022-04-20 AU AU2022260466A patent/AU2022260466A1/en active Pending
- 2022-04-20 CA CA3215771A patent/CA3215771A1/en active Pending
- 2022-04-20 KR KR1020237039881A patent/KR20240009419A/ko active Pending
- 2022-04-20 MX MX2023012368A patent/MX2023012368A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023021654A2 (pt) | 2023-12-26 |
| AU2022260466A9 (en) | 2023-11-16 |
| IL307762A (en) | 2023-12-01 |
| CA3215771A1 (en) | 2022-10-27 |
| EP4326317A1 (en) | 2024-02-28 |
| JP2024517642A (ja) | 2024-04-23 |
| US20240383947A1 (en) | 2024-11-21 |
| KR20240009419A (ko) | 2024-01-22 |
| AU2022260466A1 (en) | 2023-11-02 |
| CN117750974A (zh) | 2024-03-22 |
| WO2022223617A1 (en) | 2022-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023000411A (es) | Vacuna combinada de sars-cov-2 e influenza. | |
| MX2023012368A (es) | Vacuna de virus. | |
| MX2024009072A (es) | Vacuna contra el coronavirus. | |
| MX2022015132A (es) | Vacunas combinadas a base de acidos nucleicos. | |
| MX2022009688A (es) | Composición y métodos de vacunas de arnm contra la nueva infección por coronavirus. | |
| EP4226938A3 (en) | Coronavirus vaccine | |
| NZ791834A (en) | Vaccines against coronavirus and methods of use | |
| DE60324678D1 (de) | N t-lymphozyten und damit identifizierte hsv-antigene | |
| WO2023147092A3 (en) | Coronavirus vaccine | |
| NO20021479D0 (no) | Immunologiske signifikante herpes simplex virus antigener og metoder for å identifisere og å bruke dem | |
| PH12022552084A1 (en) | Vaccine against african swine fever virus infection | |
| MX2023000041A (es) | Composiciones y metodos para inducir una respuesta inmunitaria contra coronavirus. | |
| WO2022197720A3 (en) | Compositions and methods for treating coronavirus infection | |
| WO2003011893A3 (en) | Immunologically significant herpes simplex virus antigens and methods for using same | |
| WO2022010813A3 (en) | Enhancing immune responses through targeted antigen expression | |
| UY40490A (es) | Vacunas de combinación para prevenir y/o tratar múltiples agentes infecciosos | |
| NO20052136L (no) | Vaksine mot Hepatitt C-virus (HCV). | |
| EP4295862A3 (en) | Coronavirus vaccine | |
| MX2023003784A (es) | Peptido derivado de proteina de sars-cov-2 y vacuna que lo contiene. | |
| MX2023003377A (es) | Compuesto para aumentar la eficacia de los vectores virales. | |
| MXPA02005506A (es) | Clonacion de un gen que codifica una racemasa de aminoacido derivada de tripanosoma cruzi, y usos del mismo. | |
| DE602007010127D1 (en) | Hiv-impfstoff | |
| ZA202309368B (en) | Lentiviral vector, lentiviral particle for treating hepatitis b and its preparation method and application thereof | |
| EP4238577A3 (en) | Compositions for administration of different doses of rna | |
| WO2022226527A3 (en) | Immunogenic compositions against sars-cov-2 variants and their methods of use |